A novel kinase inhibitor, Regorafenib, blocks EGFR-dependent signaling to repress tumour metastasis in human triple-negative breast cancers
Our discovery of Regorafenib as a novel inhibitor of EGFR activation provides valuable insights for TNBC-specific anti-EGFR therapies targeting metastasis.
Authors
- C F Wang
- Wenqiang Yang (ORCID: https://orcid.org/0000-0002-2918-1859)
- Pushuai Wen
- B. Zhang (ORCID: https://orcid.org/0009-0001-3533-7784)
- Hongyu Du
- Yue Zhang (ORCID: https://orcid.org/0000-0001-7856-7451)
- Ying Liu
- Guan Wang (ORCID: https://orcid.org/0000-0003-1407-5778)
- Yangping Wang (ORCID: https://orcid.org/0000-0002-6226-0460)
- Wei Zhao
- Xiaohui Chu
- Meijing Liu
- Yajing Meng
- Hongdan Li
- Ludong Zhao
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Jining Medical University (CN)
- Jinzhou Medical University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.3389/fcell.2026.1714597
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Liaoning Province